Jamshedpur Reporter

Neuroendocrine Tumors Pipeline Report 2024 | Clinical Trials, FDA, EMA, PMDA Approvals

 Breaking News
  • No posts were found

Neuroendocrine Tumors Pipeline Report 2024 | Clinical Trials, FDA, EMA, PMDA Approvals

June 14
22:00 2024
Neuroendocrine Tumors Pipeline Report 2024 | Clinical Trials, FDA, EMA, PMDA Approvals

DelveInsight’s, “Neuroendocrine Tumors Pipeline Insight 2024” report provides comprehensive insights about 115+ companies and 130+ pipeline drugs in Neuroendocrine Tumors pipeline landscape. It covers the Neuroendocrine Tumors pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Neuroendocrine Tumors therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Explore our latest breakthroughs in Neuroendocrine Tumors research. Learn more about our innovative pipeline today! @ Neuroendocrine Tumors Pipeline Outlook

 

Key Takeaways from the Neuroendocrine Tumors Pipeline Report

  • June 2024:- ITM Solucin GmbH– The purpose of the study is to evaluate the efficacy, safety & patient-reported outcomes of peptide receptor radionuclide therapy (PRRT) with 177Lu-Edotreotide as 1st or 2nd line of treatment compared to best standard of care in patients with well-differentiated aggressive grade 2 and grade 3, somatostatin receptor-positive (SSTR+), neuroendocrine tumours of gastroenteric or pancreatic origin.
  • June 2024:- Washington University School of Medicine– High grade neuroendocrine neoplasm patients are treated with platinum doublets such as carboplatin and etoposide mimicking the current guidelines for small cell lung cancer (SCLC). Unfortunately, recurrences are common and most patients with metastatic disease succumb to it within a year.
  • June 2024:- Advanced Accelerator Applications– This is a multicenter, open-label, single-arm study to evaluate the safety and dosimetry of Lutathera in adolescent patients 12 to
  • June 2024:- Suzhou Zelgen Biopharmaceuticals Co.,Ltd– A Phase I/II Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of ZG005 in Combination With Etoposide and Cisplatin in Participants With Advanced Neuroendocrine Carcinoma.
  • DelveInsight’s Neuroendocrine Tumors pipeline report depicts a robust space with 115+ active players working to develop 130+ pipeline therapies for Neuroendocrine Tumors treatment.
  • The leading Neuroendocrine Tumors Companies such as Ipsen, Shenzhen Chipscreen Biosciences Co., Ltd., Hutchison Medipharma Limited, RayzeBio Inc., Amgen, Camurus, BeiGene, EpicentRx, GlaxoSmithKline, Crinetics Pharmaceuticals, Eli Lilly and Company, Seneca Therapeutics, ADC Therapeutics, Vyriad, Inc., and others.
  • Promising Neuroendocrine Tumors Therapies such as 177Lu-Dotatate, Nivolumab, AlphaMedix, Lutetium [177Lu] Oxodotreotide Injection, Octreotide LAR, and others.

 

Stay informed about the cutting-edge advancements in Neuroendocrine Tumors Treatments. Download for updates and be a part of the revolution in cancer care @ Neuroendocrine Tumors Clinical Trials Assessment

 

Neuroendocrine Tumors Emerging Drugs Profile

  • RYZ101: RayzeBio, Inc.

RYZ101 is an investigational, targeted RPT designed to deliver a highly potent alpha-emitting radioisotope, Actinium-225 (Ac225), to solid tumors expressing SSTR2. RYZ101 leverages DOTATATE, a known binder and linker used in other radiopharmaceutical produts. RYZ101 uses Ac225 instead of the Lu177 used in Lutathera and thus delivers hundreds of times more potency in cancer cell killing. The higher potency of RYZ101 can provide significant clinical benefit to patients. RYZ101 utilizes a proprietary and patent protected formulation. The drug is being developed for gastroenteropancreatic neuroendocrine tumor, pancreatic net, neuroendocrine tumors, extensive stage small cell lung cancer (ES-SCLC), and other tumors.

  • SVV-001: Seneca Therapeutics

SVV-001, an oncolytic virus of the genus Seneca in the Picornaviridae family. SVV-001 is characterized by its ability to replicate selectively in certain human tumor cells (“SVV-permissive cells”), namely those that express TEM8, the receptor of SVV. SVV-001 is non-pathogenic in humans and animals. SVV-001 and the Seneca genus was originally discovered in 2001 at Novartis Pharmaceuticals by Dr. Paul Hallenbeck. SVV-001 was further developed as a novel cancer therapeutic at Neotropix, Inc. SVV-001 has been extensively tested in over 30 non-clinical cancer models, including immunotherapeutic settings, and in three clinical trials for various solid cancer namely neuroendocrine tumors such as carcinoids, small cell lung cancer and a variety of pediatric cancers. These trials confirmed the safety of intravenous dosing of SVV-001 and safety along with suggestions of significant clinical benefit. Currently the drug is in Phase II stage of Clinical trial evaluation for the treatment of Neuroendocrine Tumors.

  • Voyager-V1: Vyriad, Inc.

VSV-IFNβ-NIS (Voyager V1; VV1) is derived from VSV, a bullet-shaped, negative-sense RNA virus with low human seroprevalence; it is engineered to replicate selectively in and kill human cancer cells. VV1 encodes hIFNβ to increase antitumoral immune response and tumor specificity, plus the thyroidal sodium iodide symporter NIS to allow imaging of virus. VV1 is synergistic with different anti-PD-(L)1 antibodies in several tumor models. Currently the drug is in Phase I/II stage of Clinical trial evaluation for the treatment of Neuroendocrine Tumors.

  • ADCT-701: ADC Therapeutics

ADCT-701 is an ADC composed of a humanized IgG1 antibody against human DLK-1, site-specifically conjugated using Glycoconnect technology to PL1601, which contains a valine-alanine cleavable linker and the PBD dimer cytotoxin SG3199. In vitro, ADCT-701 demonstrated potent cytotoxicity in a panel of human cancer cell lines of different origin and levels of DLK-1, while its potency was strongly reduced in DLK-1-negative cell lines. In vivo, ADCT-701 showed potent anti-tumor activity in the DLK1-expressing neuroblastoma-derived SK-N-FI xenograft in which a single dose of ADCT-701 at 0.5 or 1 mg/kg showed dose-dependent anti-tumor activity compared to the vehicle- and isotype control ADC-treated mice. Currently the drug is in Phase I stage of Clinical trial evaluation for the treatment of Neuroendocrine Tumors.

 

Learn more about Neuroendocrine Tumors Drugs opportunities in our groundbreaking metastatic prostate cancer research and development projects @ Neuroendocrine Tumors Unmet Needs

 

Neuroendocrine Tumors Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

  • Intravenous
  • Subcutaneous
  • Oral
  • Intramuscular

 

Neuroendocrine Tumors Products have been categorized under various Molecule types such as

  • Monoclonal antibody
  • Small molecule
  • Peptide

 

Discover the latest advancements in Neuroendocrine Tumors treatment by visiting our website. Stay informed about how we’re transforming the future of oncology @ Neuroendocrine Tumors Market Drivers and Barriers, and Future Perspectives

 

Scope of the Neuroendocrine Tumors Pipeline Report

  • Coverage- Global
  • Neuroendocrine Tumors Companies- Ipsen, Shenzhen Chipscreen Biosciences Co., Ltd., Hutchison Medipharma Limited, RayzeBio Inc., Amgen, Camurus, BeiGene, EpicentRx, GlaxoSmithKline, Crinetics Pharmaceuticals, Eli Lilly and Company, Seneca Therapeutics, ADC Therapeutics, Vyriad, Inc., and others.
  • Neuroendocrine Tumors Therapies- 177Lu-Dotatate, Nivolumab, AlphaMedix, Lutetium [177Lu] Oxodotreotide Injection, Octreotide LAR, and others.
  • Neuroendocrine Tumors Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Neuroendocrine Tumors Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

 

For a detailed overview of our latest research findings and future plans, read the full details of Neuroendocrine Tumors pipeline on our website @ Neuroendocrine Tumors Emerging Drugs and Companies

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Neuroendocrine Tumors: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Neuroendocrine Tumors– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. RYZ101: RayzeBio, Inc.
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. SVV-001: Seneca Therapeutics
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. ADCT-701: ADC Therapeutics
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Product Name: Company Name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Neuroendocrine Tumors Key Companies
  21. Neuroendocrine Tumors Key Products
  22. Neuroendocrine Tumors- Unmet Needs
  23. Neuroendocrine Tumors- Market Drivers and Barriers
  24. Neuroendocrine Tumors- Future Perspectives and Conclusion
  25. Neuroendocrine Tumors Analyst Views
  26. Neuroendocrine Tumors Key Companies
  27. Appendix

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/